2020
Association of a Prior Psychiatric Diagnosis With Mortality Among Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Infection
Li L, Li F, Fortunati F, Krystal JH. Association of a Prior Psychiatric Diagnosis With Mortality Among Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Infection. JAMA Network Open 2020, 3: e2023282. PMID: 32997123, PMCID: PMC7527869, DOI: 10.1001/jamanetworkopen.2020.23282.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overBetacoronavirusCerebrovascular DisordersCohort StudiesComorbidityCoronavirus InfectionsCOVID-19Diabetes MellitusFemaleHeart FailureHIV InfectionsHospitalizationHumansKaplan-Meier EstimateKidney DiseasesLiver DiseasesMaleMental DisordersMiddle AgedMyocardial InfarctionNeoplasmsPandemicsPneumonia, ViralProportional Hazards ModelsRisk FactorsSARS-CoV-2United States
2014
Differences in Treatment Effect Among Clinical Subgroups in a Randomized Clinical Trial of Long-Acting Injectable Risperidone and Oral Antipsychotics in Unstable Chronic Schizophrenia
Leatherman SM, Liang MH, Krystal JH, Lew RA, Valley D, Thwin SS, Rosenheck RA. Differences in Treatment Effect Among Clinical Subgroups in a Randomized Clinical Trial of Long-Acting Injectable Risperidone and Oral Antipsychotics in Unstable Chronic Schizophrenia. The Journal Of Nervous And Mental Disease 2014, 202: 13-17. PMID: 24375206, DOI: 10.1097/nmd.0000000000000069.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdultAgedAntipsychotic AgentsChronic DiseaseDrug Administration ScheduleFemaleHospitalizationHumansInjections, IntramuscularMaleMiddle AgedProportional Hazards ModelsPsychotic DisordersQuality of LifeRisk AssessmentRisperidoneSchizophreniaSchizophrenic PsychologySeverity of Illness IndexSubstance-Related DisordersTreatment OutcomeConceptsQuality of lifeOral antipsychoticsOral treatmentInjectable risperidoneCox regressionTreatment effectsLong-Acting Injectable RisperidoneBody mass indexPsychiatric service useSubstance abuse outcomesSubstance use outcomesLAI risperidonePrimary endpointStudy entryWhite patientsClinical outcomesMass indexUnstable patientsMedication compliancePsychiatric rehospitalizationChronic schizophreniaClinical trialsClinical subgroupsPsychiatric hospitalizationPsychiatric symptoms
2012
Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia.
Barnett PG, Scott JY, Krystal JH, Rosenheck RA. Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia. The Journal Of Clinical Psychiatry 2012, 73: 696-702. PMID: 22697193, DOI: 10.4088/jcp.11m07070.Peer-Reviewed Original ResearchMeSH KeywordsAntipsychotic AgentsComparative Effectiveness ResearchCost-Benefit AnalysisDelayed-Action PreparationsDouble-Blind MethodDrug CostsFemaleHealth Care CostsHospitalizationHumansInjectionsKaplan-Meier EstimateMaleMiddle AgedModels, EconometricPsychotic DisordersRisperidoneSchizophreniaUnited StatesVeteransConceptsTotal health care costsHealth care costsLAI risperidoneMedication costsControl groupCare costsVeterans Health Administration patientsHealth care utilizationHealth Related QualityStructured Clinical InterviewUS Medicaid programCase report formsMultisite clinical trialQuality of WellExperimental groupOral antipsychoticsAdverse eventsCare utilizationInjectable risperidoneOutpatient costsHospitalization costsClinical trialsRelated qualityLAI groupPhysician's choice
2011
Long-Acting Risperidone and Oral Antipsychotics in Unstable Schizophrenia
Rosenheck RA, Krystal JH, Lew R, Barnett PG, Fiore L, Valley D, Thwin SS, Vertrees JE, Liang MH. Long-Acting Risperidone and Oral Antipsychotics in Unstable Schizophrenia. New England Journal Of Medicine 2011, 364: 842-851. PMID: 21366475, DOI: 10.1056/nejmoa1005987.Peer-Reviewed Original ResearchConceptsInjectable risperidoneOral antipsychoticsQuality of lifeSchizoaffective disorderPsychiatrist's choiceSecond-generation antipsychotic agentsMore adverse eventsMore extrapyramidal symptomsPrimary end pointNeurologic side effectsExtrapyramidal adverse effectsRate of hospitalizationVeterans Affairs systemSocial Performance ScaleAdverse eventsExtrapyramidal symptomsOral treatmentAntipsychotic agentsUnstable diseasePsychiatric symptomsHigh riskHospitalizationSide effectsPatientsPsychiatric hospital
2007
Effect of Memantine on Cue-Induced Alcohol Craving in Recovering Alcohol-Dependent Patients
Krupitsky EM, Neznanova O, Masalov D, Burakov AM, Didenko T, Romanova T, Tsoy M, Bespalov A, Slavina TY, Grinenko AA, Petrakis IL, Pittman B, Gueorguieva R, Zvartau EE, Krystal JH. Effect of Memantine on Cue-Induced Alcohol Craving in Recovering Alcohol-Dependent Patients. American Journal Of Psychiatry 2007, 164: 519-523. PMID: 17329479, DOI: 10.1176/ajp.2007.164.3.519.Peer-Reviewed Original ResearchConceptsNMDA receptor antagonist memantineAlcohol cue-induced cravingEffects of memantineAspartic acid (NMDA) glutamate receptorsDose-related fashionDouble-blind conditionsNMDA receptor functionNMDA receptor antagonistAlcohol-dependent patientsAlcohol cuesCue-induced alcoholTreatment of alcoholismCue-induced cravingEthanol-like effectsReceptor antagonistAlcohol-dependent inpatientsGlutamate receptorsMemantineAlcohol cravingMotivational disturbancesRandomized orderReceptor functionBehavioral effectsSubjective effectsTest day
1998
Creatine Kinase Elevations and Aggressive Behavior in Hospitalized Forensic Patients
Hillbrand M, Spitz R, Foster H, Krystal J, Young J. Creatine Kinase Elevations and Aggressive Behavior in Hospitalized Forensic Patients. Psychiatric Quarterly 1998, 69: 69-82. PMID: 9536476, DOI: 10.1023/a:1022137524475.Peer-Reviewed Original ResearchConceptsCK levelsAntipsychotic medicationCreatine kinaseViolent patientsCreatine kinase elevationHigh CK levelsAggressive behaviorProspective studyPatientsClinical diagnosisBiological markersPotential predictorsForensic patientsForensic hospitalMedicationsViolent behaviorSubsequent violenceLevelsHospitalDiagnosis
1996
Recurrent self-injurious behavior in forensic patients
Hillbrand M, Young J, Krystal J. Recurrent self-injurious behavior in forensic patients. Psychiatric Quarterly 1996, 67: 33-45. PMID: 8623037, DOI: 10.1007/bf02244273.Peer-Reviewed Original ResearchConceptsSelf-injurious behaviorForensic patientsPsychiatric populationsSelf-injurious patientsGreat therapeutic challengeRecurrent self-injurious behaviorSelf-destructive patientsLonger hospitalizationTherapeutic challengeForensic psychiatric populationHigh prevalencePatientsVigorous interventionDiagnostic measuresPresent studyHospitalizationPopulationPrevalenceSerotonergic and noradrenergic dysregulation in alcoholism: m- chlorophenylpiperazine and yohimbine effects in recently detoxified alcoholics and healthy comparison subjects
Krystal JH, Webb E, Cooney NL, Kranzler HR, Southwick SW, Heninger GR, Charney DS. Serotonergic and noradrenergic dysregulation in alcoholism: m- chlorophenylpiperazine and yohimbine effects in recently detoxified alcoholics and healthy comparison subjects. American Journal Of Psychiatry 1996, 153: 83-92. PMID: 8540598, DOI: 10.1176/ajp.153.1.83.Peer-Reviewed Original ResearchConceptsHealthy comparison subjectsAlcoholic patientsComparison subjectsCortisol responseYohimbine infusionPostsynaptic noradrenergic receptorsBlood pressure responseDouble-blind conditionsNoradrenergic reactivitySaline placeboNoradrenergic receptorsMHPG levelsIntravenous infusionYohimbine effectMHPG responsePlasma levelsNoradrenergic systemPersistent alterationsNoradrenergic dysregulationMale inpatientsDrug effectsNeuroendocrine responsivityPatientsPhysiologic responsesPlasma cortisol
1995
Tryptophan depletion and attenuation of cue-induced craving for cocaine
Satel SL, Krystal JH, Delgado PL, Kosten TR, Charney DS. Tryptophan depletion and attenuation of cue-induced craving for cocaine. American Journal Of Psychiatry 1995, 152: 778-783. PMID: 7726319, DOI: 10.1176/ajp.152.5.778.Peer-Reviewed Original ResearchConceptsCue-induced cravingTryptophan depletionPlacebo conditionPotent serotonin reuptake blockerCue exposureSerotonin reuptake blockersDouble-blind designAmino acid drinkVisual analogue ratingsCocaine-dependent patientsAnalogue ratingsReuptake blockerAcute reductionPlasma levelsSerotonergic systemMale inpatientsAcid drinkTryptophan levelsDrug usePatientsCocaine useCocaineRelapseCravingTest sessions
1994
Specificity of Ethanollike Effects Elicited by Serotonergic and Noradrenergic Mechanisms
Krystal JH, Webb E, Cooney N, Kranzler HR, Charney DS. Specificity of Ethanollike Effects Elicited by Serotonergic and Noradrenergic Mechanisms. JAMA Psychiatry 1994, 51: 898-911. PMID: 7944878, DOI: 10.1001/archpsyc.1994.03950110058008.Peer-Reviewed Original ResearchConceptsVisual analog scaleAnalog scaleScale scoreVisual analog scale scoreYohimbine hydrochlorideAnalog scale scoreDouble-blind conditionsEffect of mCPPReceptor partial agonistEffects of ethanolNoradrenergic mechanismsIntravenous infusionPlasma levelsSerotonergic systemNoradrenergic systemPlaceboDiscriminative propertiesMale inpatientsYohimbinePlasma prolactinCortisol levelsPartial agonistSerotonergic contributionAlcohol dependenceDays of testingAffective Reactivity of Language in Schizophrenia
DOCHERTY N, EVANS I, SLEDGE W, SEIBYL J, KRYSTAL J. Affective Reactivity of Language in Schizophrenia. The Journal Of Nervous And Mental Disease 1994, 182: 98-103. PMID: 8308539, DOI: 10.1097/00005053-199402000-00006.Peer-Reviewed Original ResearchClinical Predictors of Self-Mutilation in Hospitalized Forensic Patients
HILLBRAND M, KRYSTAL J, SHARPE K, FOSTER H. Clinical Predictors of Self-Mutilation in Hospitalized Forensic Patients. The Journal Of Nervous And Mental Disease 1994, 182: 9-16. PMID: 8277305, DOI: 10.1097/00005053-199401000-00003.Peer-Reviewed Original ResearchConceptsSelf-mutilating patientsForensic patientsOvert Aggression ScaleProbability of recurrenceHistory of suicideMale forensic patientsInpatient courseClinical predictorsMale forensic inpatientsClinical correlatesSame hospitalHigh riskPatientsHigh dosesNeurological characteristicsPersonality disorderSelf-MutilationMaximum security hospitalMental retardationRecurrenceForensic inpatientsHospitalAggressive behaviorHistory of violenceInsanity acquittees
1993
Effects of Cocaine on Hospital Course in Schizophrenia
SEIBYL J, SATEL S, ANTHONY D, SOUTHWICK S, KRYSTAL J, CHARNEY D. Effects of Cocaine on Hospital Course in Schizophrenia. The Journal Of Nervous And Mental Disease 1993, 181: 31-37. PMID: 8093475, DOI: 10.1097/00005053-199301000-00006.Peer-Reviewed Original ResearchConceptsSubstance useSuicidal ideationCocaine useLifetime drug use historyAvailable hospital recordsHigher hospitalization ratesHigher neuroleptic dosesNon-using patientsEffects of cocainePoor illness courseDrug use historySubstance use patternsHigh rateSchizophrenia clinicHospital courseNeuroleptic doseHospital recordsHospitalization ratesIllness courseInpatient chartsNeuroleptic dosesPsychiatric hospitalizationNeuroleptic dosingHospitalizationSchizophrenic patients
1991
Clinical phenomenology and neurobiology of cocaine abstinence: a prospective inpatient study
Satel SL, Price LH, Palumbo JM, McDougle CJ, Krystal JH, Gawin F, Charney DS, Heninger GR, Kleber HD. Clinical phenomenology and neurobiology of cocaine abstinence: a prospective inpatient study. American Journal Of Psychiatry 1991, 148: 1712-1716. PMID: 1957935, DOI: 10.1176/ajp.148.12.1712.Peer-Reviewed Original ResearchConceptsHomovanillic acidGrowth hormoneRating ScaleGH valuesNormal subjectsCentral dopamine functionProspective inpatient studySerial blood samplesVisual analog scaleDSM-III-R cocaine dependenceSignificant decreaseSymptom Rating ScaleShort clinical rating scalesClinical rating scalesBeck Depression InventoryPhysical Symptoms ScalePatients prolactinInpatient managementSuch patientsAnalog scaleInpatient studyDopaminergic functionPatient levelBlood samplesPharmacological agents